Kornimate/medical-research-clean huggingface dataset:
clinical sciences research proposal- the effect of physical exercise on pcos overweight female adolescents

Conditions: Polycystic Ovary Syndrome; Overweight

Summary: the poly cystic ovary syndrome (pcos), is one of the most common reasons for subfertility, oligomenorrhea and amenorrhea. with the occurrence of 6-20% of the general adult women population. one of the main criteria of this syndrome is a hyper androgenic state. more than 50% of women who have pcos are overweight. in the teenage population, pcos is common in 5-10% of teenage girls. a recent research has shown that elite athlete teenage girls have higher serum androgen levels, especially in anaerobic types of sport. the purpose of this experiment is to examine the reaction of teenage pcos overweight girls towards anaerobic exercise. to determine if their hyperandrogenic state is more adapted to excel in anaerobic exercise compared to teenage overweight girls without pcos.

30 teenage and young adult females, aged 10-25 years old. the minimum hormonal age for inclusion is menarche. overweight- with a body mass index (bmi) percentage above 85%, divided into 2 groups: 15 girls with diagnosed pcos, and 15 girls without diagnosed pcos, without any other medical comorbidities. followed at the pediatric endocrinology unit. the 2 groups would participate in 2 anaerobic tests to evaluate their performances. the data received will be used to evaluate their anaerobic attributes, and for comparison between the 2 groups to determine any differences. the participants will be asked to refrain from any form of physical exercise during the previous day. after explanation to the patient and his parent and obtaining an informed consent, the participants will start the tests. the first test is the repeated sprint test: the participant will run a distance of 40 meters, for 6 repetitions. the optimal running time will be calculated, total running time and the performance decrement of the run will be calculated. after that, there will be a 1-1.5 hours resting phase. the second test is the "wingate test"- the participants will be instructed to pedal at a maximal pace for 30 seconds on an ergometric bicycle against a resistance adjusted according to their bmi. the peak anaerobic power, the mean anaerobic power and the fatigue index will be calculated.

Eligibility criteria:
inclusion criteria: * post menarche female * pcos diagnosis * overweight- bmi above 85 percent. exclusion criteria: * inability to complete the physical activity due to health issues * thyroid dysfunction (hyper-, hypo-) * hyperprolactinemia * congenital adrenal hyperplasia
in vivo egfr molecular classification and treatment response

Conditions: Molecular Imaging

Summary: the investigators developed 18f-mpg as a targeted molecular imaging agent for noninvasive and repeatable detecting egfr-activating mutational status. and use 18f-mpg to monitor egfr-tkis and chemotherapy treatment efficiency.

the goal of investigators were to evaluate the use of 18f-mpg as a novel pet/ct radiotracer to monitor egfr-activating mutational status and identify egfr-tkis benefit nsclc patients. the investigators want to evaluated the use of 18f-mpg in lung cancer imaging in adult nsclc patients with different egfr mutational status of primary and metastatic cancers. and the investigators want to evaluated the use of 18f-mpg in adult nsclc patients with egfr mutational status received non-treatment, egfr-tkis and chemotherapy.

Eligibility criteria:
inclusion criteria: * advanced nsclc * 18 years or older * a life expectancy of at least 12 weeks * presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (ct) * written informed consent exclusion criteria: * claustrophobia * pregnancy * metal implants in the thorax
topical steroid treatment after posterior lamellar corneal transplantation

Conditions: Endothelial Dystrophy; Secondary Bullous Keratopathy; Posterior Lamellar Keratoplasty; Descemet's Stripping Endothelial Keratoplasty

Summary: after corneal transplantation, topical corticosteroids are used to reduce the risk of rejection. however, the optimal postoperative treatment regimen is unknown. in most cases, a topical steroid is administered for at least 6 months after surgery, but it remains to be determined whether potent steroids offer better protection than weak steroids. also, the length of the treatment is debated. since the use of steroids is not without potential serious ocular side effects, it is of considerable importance to investigate these problems. the study aims to examine the frequency of rejection episodes after posterior lamellar keratoplasty; specifically comparing a short course of potent steroids versus a long course of weak steroids.


Eligibility criteria:
inclusion criteria: * patients treated for primary or secondary corneal endothelial failure at the department of ophthalmology, aarhus university hospital exclusion criteria: * not fulfilling the above
national mammography database

Conditions: Breast Cancer Screening and Diagnosis

Summary: the national mammography database (nmd) leverages data that radiology practices are already collecting under federal mandate by providing them with comparative information for national and regional benchmarking. participants receive semi-annual feedback reports that include important benchmark data such as cancer detection rates, positive predictive value rates and recall rates. participation in the nmd is free to breast imaging center of excellence (bicoe) facilities.


Eligibility criteria:
inclusion criteria: * all exclusion criteria: * none
program of integrated care for patients with chronic obstructive pulmonary disease and multiple comorbidities

Conditions: Chronic Obstructive Pulmonary Disease; Multiple Comorbidity

Summary: many patients with chronic obstructive pulmonary disease (copd) also have other diseases referred to as comorbidities. often these patients require health care by a variety of health care professionals from services linked to hospitals and in the community. unfortunately, sometimes it may be difficult for these patients to receive appropriate care in a timely manner resulting in a trip to the emergency department. as well, patients may benefit from education that enables them to recognize early signs indicating they are getting sicker and to self-manage their disease. our study will examine a strategy that includes a case manager who will make weekly phone contact with copd patients with comorbidity that present either to the emergency department or are admitted to hospital. weekly contact will focus on teaching patients to recognize worsening symptoms and self-management strategies. the case manager will work with patients, caregivers, community health care providers and hospital specialists to promote communication and optimize care delivery. the investigators will examine the impact of our intervention on the need for emergency department visits and hospital admission. the investigators will also examine the impact on patients' health related quality of life, number of copd exacerbations, and disease progression.


Eligibility criteria:
inclusion criteria: * copd defined as chronic irreversible airflow limitation with fev1 \< lower limit of normal for age as % predicted and a fev1/fvc ratio \< than lower limit of normal (usually 70%) \[5\] plus ≥ 2 comorbidities commonly associated with copd as identified in the canadian thoracic society copd guidelines\* 1. cardiovascular disease 2. osteopenia and osteoporosis 3. glaucoma and cataracts 4. cachexia and malnutrition 5. peripheral muscle dysfunction 6. lung cancer 7. metabolic syndrome (diabetes mellitus) 8. depression 9. chronic kidney disease or other conditions as primary admitting/presenting diagnosis + copd as significant comorbidity + ≥ 1 other comorbidity that 1. get admitted to participating hospital; or 2. present to participating hospital ed; or 3. have first referral to respiratory centre/respirology team and have 1. ≥ 1 ed presentation/hospital admission in previous 12 months 2. ≥ 50 years age exclusion criteria: 1. no access to primary care physician 2. primary diagnosis of asthma 3. terminal diagnosis (metastatic disease with a life expectancy of ≤ 6 months) 4. dementia and absence of family caregiver able to assist with activation of the action plan and feedback on ongoing status and care coordination 5. uncontrolled psychiatric illness 6. inability to understand, read, and write english 7. no access to a phone 8. inability to attend follow up at one of the participating sites

Keywords: copd case management
rn624 for pain of post-herpetic neuralgia

Conditions: Neuralgia, Postherpetic

Summary: this study will test the efficacy and safety of two doses levels of rn624 versus placebo for the relief of pain caused by post-herpetic neuralgia (phn).


Eligibility criteria:
inclusion criteria: * male or female of any race, at least 18 years of age. * patients must have pain present for more than 3 months after healing of the herpes zoster skin rash. * has a pain score at screening that qualifies. * completes at least 3 average daily pain diaries during the 3 days prior to randomization and has an average pain level that qualifies. * body mass index less than or equal to 39 kg/m2. * if female, is post-menopausal, surgically sterile, or uses adequate contraception consisting of 2 forms of birth control, one of which must be barrier method, is not lactating, and is not breastfeeding. * male patients must agree that female spouses/partners will use contraception as defined above or be of nonchildbearing potential (post-menopausal or surgically sterile). * patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * patients must consent in writing to participate in the study. exclusion criteria: * patients who cannot discontinue the use of other pain medications during the screening period and during the study. * disqualifying scores on questionnaires. * other moderate to severe pain from other conditions. * history of allergic or anaphylactic reaction to antibodies. * use of biologics, including any live vaccines within 3 months of the week prior to the baseline visit. * unable to use acetaminophen. * disqualify laboratory values, hepatitis b or c or hiv. * patients that have had a stroke or tias, dementia, epilepsy or seizures, or peripheral neuropathy from other conditions. * significant cardiac disease within 3 months of the study such as angina, heart attack, congestive heart failure, and other cardiac problems. * cancer other than basal cell or squamous cell carcinoma. * fails a urine test for illegal drugs including prescription drugs without a prescription. * plans for surgery during the study. * history of alcoholism or drug abuse in the past two years. * surgery for post-herpetic neuralgia. * any condition that the investigator feels would put the safety of the patient at risk.

Keywords: monoclonal antibody
intrapleural minocycline following simple aspiration for primary spontaneous pneumothorax

Conditions: Pneumothorax

Summary: the optimal initial management of primary spontaneous pneumothorax (psp) remains controversial. this study was conducted to evaluate the safety and efficacy of additional minocycline pleurodesis after successful aspiration of the first episode of psp.

primary spontaneous pneumothorax (psp) most commonly occurs in young, tall, lean males. the estimated recurrence rate is 23-50% after the first episode. the high recurrence rate stimulated the development of many different therapeutic approaches, ranging from conservative treatment such as observation to more invasive therapies such as surgery, and optimal treatment of patients presenting with a first episode of psp remains controversial. in the recently published british thoracic society (bts) guidelines, simple aspiration is recommended as the first line treatment for all psp requiring intervention because this treatment provided the advantage of reduced hospital admission rate and reduced length of hospital stay when compared with chest tube drainage. however, the recurrence rate of this procedure was around 30%, making it inappropriate as a standard of care. intrapleural instillation of a chemical irritant (chemical pleurodesis) is an effective way to reduce the rates of recurrent spontaneous pneumothorax in surgical and non-surgical patients. previously, chemical pleurodesis had usually been administrated through chest tube or thoracoscopy. administration of sclerosing agents through intravenous needle catheter or pigtail catheter after simple aspiration had never been reported and the safety and efficacy remained unknown. because the recurrence rate after simple aspiration remains high, we began to instill minocycline into the pleural cavity through the pigtail or intravenous needle catheter since december 2005 to determine if this adjuvant is effective in reducing the rate of recurrence. in the present study, we report our experience of minocycline pleurodesis in treating first episode of psp after successful aspiration of pneumothorax. the effects of this adjuvant therapy were evaluated by comparing the outcomes of the patients who underwent simple aspiration alone with those who underwent additional minocycline pleurodesis.

Eligibility criteria:
inclusion criteria: * primary spontaneous pneumothorax patients who underwent manual aspiration as their initial treatment were selected. exclusion criteria: * patients with a previous history of spontaneous pneumothorax, \>50 years of age, or with preexisting pulmonary diseases were excluded. patients with unsuccessful aspiration requiring further chest tube insertion or thoracoscopic operation were also excluded

Keywords: minocycline pleurodesis aspiration pneumothorax primary spontaneous pneumothorax first attack successful aspiration
study on effects of testosterone replacement therapy in hypogonadal type 2 diabetic patients" (seth2)

Conditions: Hypogonadism, Male; Diabetes Mellitus, Type 2; Obesity

Summary: aim of the study was to investigate the effects of testosterone replacement therapy on components of metabolic syndrome, vascular function and morphology, grade of non-alcoholic fatty liver disease (nafld), bone mineral density (bmd) and health-related quality of life.

studies have shown that approximately 50 % of older obese males, who are being treated for diabetes mellitus type 2, also exhibit low testosterone levels. hypogonadism negatively affects glycemic control, exacerbates early cardio-vascular disease, causes osteoporosis, erectile disfunction, reduces lean body mass, accelerates the accumulation of visceral fat and leads to obesity. patients with diabetes mellitus type 2 and confirmed hypogonadism were enrolled into this randomized, double-blind, placebo-controlled clinical study. placebo group patients were receiving placebo throughout the first year of this study and testosterone group patients were receiving testosterone undecanoate during first year. both groups were receiving testosterone undecanoate throughout the second year of this study.

Eligibility criteria:
inclusion criteria: * men aged \> 35 years * body mass index \> 30 kg/m2 * confirmed hypogonadism * type 2 diabetes mellitus treated with non-insulin therapy exclusion criteria: * previously treated hypogonadism * the 2 diabetes mellitus treated with insulin therapy * a history of current prostate or breast cancer * severe benign prostatic hyperplasia * elevated prostate-specific antigen (psa \> 4.0 lg/l) * severe heart failure * acute coronary event or procedure during the six months leading up to the study * chronic obstructive lung disease * hypothyroidism * severe obstructive sleep apnea (osa) * active infection * rheumatoid arthritis

Keywords: testosterone hypogonadism diabetes mellitus visceral obesity insulin resistance metabolic syndrome nafld endothelial function
expanded access study with peginterferon alfa-2a (pegasys) in participants with chronic myelogenous leukemia (cml)

Conditions: Myelogenous Leukemia, Chronic

Summary: this study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with cml who have previously participated in peginterferon alfa-2a study ml16544 (nct number not available), no16006 (nct number not available) or ml17228 (nct number not available) and treating physician has decided to continue treatment with peginterferon alfa-2a within the frame of another clinical study.


Eligibility criteria:
inclusion criteria: * participants with cml * previous participation in studies: ml16544, no16006 or ml17228; for which the treating physician recommends a continuation of the study drug according to defined minimal criteria exclusion criteria: * major protocol violator in the participated study prior to participation in this study
safety of low and very low carbohydrate diets in young children with type 1 diabetes

Conditions: Type 1 Diabetes Mellitus; Diet Modification; Child, Only

Summary: the purpose of the study is to evaluate the safety of short-term (6 month) low or very-low carbohydrate diets in prepubertal children 2 to \<12 years old with type 1 diabetes. participants will be randomized to either low carbohydrate diet (carbohydrate makes up 30-39% of total daily calories) or very-low carbohydrate diet (carbohydrates are 20-29% of total daily calories). the investigators will evaluate metabolic effects of these diets by measuring the counter-regulatory hormone response to hypoglycemia at baseline and again at 3 months. other outcomes include diabetes control as measured by hba1c, growth and weight gain, lipid profiles, and body composition.

the purpose of the study is to evaluate the safety of short-term (6 month) low or very-low carbohydrate diets in prepubertal children 2 to \<12 years old with type 1 diabetes. participants will be randomized to either low carbohydrate diet (carbohydrate makes up 30-39% of total daily calories) or very-low carbohydrate diet (carbohydrates are 20-29% of total daily calories). the investigators will evaluate metabolic effects of these diets by measuring the counter-regulatory hormone response to hypoglycemia at baseline and again at 3 months. other outcomes include diabetes control as measured by hba1c, growth and weight gain, lipid profiles, and body composition. participants will be admitted to the clinical research center at baseline and 3 months. gradual reduction in serum glucose to under 80 mg/dl will be achieved by an increase in their insulin infusion rate through their insulin pump. plasma glucose, catecholamines (epinephrine, norepinephrine), glucagon, and serum ketones are measured at baseline and after glucose is below 80 mg/dl. all subjects will have lipid evaluation and body composition (dxa scan) at baseline and 6 months. subjects' growth will be evaluated by comparing their height and weight z-score before and after the 6 months of diet intervention. change in growth velocity will also be assessed. during the study, participants not already using continuous glucose monitoring will be placed on dexcom g5 to monitor blood sugars regularly. subjects will also be monitoring serum ketones at home regularly.

Eligibility criteria:
inclusion criteria * prepubertal children 2 to \<12 years old (i.e., before 12th birthday) * type 1 diabetes for at least 6 months * patients must be using insulin pump therapy * not presently on low carbohydrate diet exclusion criteria * on low or very low carbohydrate diet * history of endocrine or metabolic disorder that could affect counter-regulation (well-controlled hypothyroidism is acceptable if on stable dose of l-thyroxine for ≥3 months) * history of metabolic disorder affection lipid metabolism * severe hypoglycemic event in past 3 months

Keywords: type 1 diabetes low carbohydrate diets insulin pump therapy continuous glucose monitoring
psychotherapy treatment of deployment-related ptsd in primary care settings

Conditions: Post-Traumatic Stress Disorders; Stress Disorders; Combat Disorders

Summary: the purpose of this study is to evaluate cognitive-behavioral therapy (cbt) for deployment-related post-traumatic stress disorder (ptsd) that can be used by behavioral health consultants working with service members in the primary care clinic. cbt is a well-researched, very effective individual (one-to-one) treatment that is designed to help people to directly deal with traumatic events they have suffered in the past, including combat. many service members prefer to see behavioral health providers in primary care rather than the mental health clinic. the researchers hope to learn if a brief treatment for ptsd in primary care can be just as useful as more traditional treatment given in the mental health clinic. this study will enroll approximately 45 participants overall; with approximately 30 participants at wilford hall medical center or brooke army medical center, and 15 participants to be enrolled at the south texas veterans health care system over a period of one year.


Eligibility criteria:
inclusion criteria: * the target population for the study is active duty, reserve, guard, separated, or retired oif/oef veterans (minimum age 18 and english speaking) in the primary care population who are symptomatic for deployment-related ptsd and interested in treatment. * symptomatic for ptsd will be defined as a minimum score of 32 on the ptsd checklist - military (pcl-m). exclusion criteria: * the exclusion criteria are those that would normally apply for standard of care behavioral health consultation in an integrated primary care clinic. * these exclusion criteria are moderate to severe suicide risk, current alcohol dependence, psychotic disorder, significant dissociative disorder, and severe brain injury.

Keywords: active duty afghanistan anger anxiety avoidance bamc brooke army medical center cognitive behavioral therapy combat combat disorder coping counseling counselor deployment depression exposure fear feeling alone flashbacks guard guilt hospitalization iraq mental health military military member military personnel neuroses nightmares oef oif prolonged exposure therapy psychiatric psychiatric medication psychological distress psychotherapy reserve retired sadness separated sleeplessness soldier stress stress disorder stress management strong star suicidal suicide therapy trauma traumatic event trouble sleeping veteran veterans war whmc wilford hall medical center ptsd posttraumatic stress disorders
optimizing aspirin and clopidogrel therapy (bochum clopidogrel and aspirin plan)

Conditions: Coronary Artery Disease

Summary: dual antiplatelet therapy with acetylsalicylic acid (asa, aspirin) and clopidogrel is of great importance for treatment following coronary stenting. unfortunately the variable platelet inhibitory effectiveness compromises the antithrombotic benefit of dual antiplatelet therapy. the aim of this prospective single centre study was to reduce the low response incidence of dual antiplatelet therapy with asa and clopidogrel based on a standardized therapy algorithm.

platelet function testing using whole blood aggregometry was performed 48 hours following coronary stenting (either acute coronary syndromes or stable coronary artery disease). the antiplatelet therapy included a loading dose of 600 mg clopidogrel and 500 mg asa, followed by 75 mg clopidogrel and 100 mg asa once daily. clopidogrel low-response (clr) and/or asa (asa low response) were treated according to a structured therapy plan.

Eligibility criteria:
inclusion criteria: * patients with stable coronary artery disease (cad) or acute coronary syndromes (acs) following percutaneous coronary intervention (pci) exclusion criteria: * abnormal platelet count in patients, * severe liver disorders, * current gastrointestinal disorders, * current infections, * congestive heart failure, * known bleeding disorders, * treatment with bivalirudin or glycoprotein iib/iiia antagonists within the last 7 days.

Keywords: clopidogrel asa low response resistance